Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dioxane SCHEMBL2949971 | 1.00 | TTR (0.43) | TTRTDP1KDM1ATSHRLMNA | |
| Dioxane SCHEMBL10324821 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| Dioxane SCHEMBL8149387 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| Dioxane SCHEMBL3104036 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| SCHEMBL3743823 | 0.87 | — | — | |
| Tetrahydrofuran SCHEMBL2361115 | 0.87 | ALDH1A1 (0.50) | TDP1KDM1A | |
| Dioxane SCHEMBL299082 | 0.86 | TDP1 (0.34) | TTRTDP1TSHRLMNAGAA | |
| SCHEMBL7703561 | 0.84 | ALDH1A1 (0.47) | TDP1 | |
| SCHEMBL6814772 | 0.84 | ALDH1A1 (0.47) | TDP1 | |
| Tetrahydrofuran SCHEMBL5235661 | 0.84 | ALDH1A1 (0.47) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1181299-B1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20020193320-A1 | C-2 modified erythromycin derivatives | ABBOTT LABORATORIES | 2002-12-19 | — | — | US | disclosed |
| EP-1181299-A1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000069875-A9 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2000069875-A1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193320-A1 | C-2 modified erythromycin derivatives | CYP2D6, CYP1A2, CYP2B6 | TTR 2537/4885TDP1 3802/4885KDM1A 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.